用尼妥珠单抗阻断表皮生长因子受体：一种治疗新冠肺炎的新策略。
Blocking EGFR with nimotuzumab: a novel strategy for COVID-19 treatment.
作者信息
Londres Henrry Diaz, Armada Jorge Jiménez, Martínez Aray Hernández, Abdo Cuza Anselmo A, Sánchez Yamilka Hernández, Rodríguez Aylin Granado, Figueroa Sarahy Sepúlveda, Llanez Gregorich Egda M, Torres Lahera Mery L, Peire Francisco Gómez, González Teresita Montero, González Yaneth Zamora, Añé Kouri Ana L, Palomo Addys González, Concepción Mayelin Troche, Pérez Loipa Medel, Luaces-Alvarez Patricia Lorenzo, Iglesias Daymys Estévez, Hernández Danay Saavedra, Suzarte Mayra Ramos, Ramos Tania Crombet
机构信息
Julio Trigo Hospital, Havana, Cuba.
Salvador Allende Hospital, Havana, Cuba.
出版信息
Immunotherapy. 2022 May;14(7):521-530. doi: 10.2217/imt-2022-0027. Epub 2022 Mar 21.
Lung injury and STAT1 deficit induce EGFR overexpression in SARS-CoV-2 infection. A phase I/II trial was done to evaluate the safety and preliminary effect of nimotuzumab, an anti-EGFR antibody, in COVID-19 patients. Patients received from one to three infusions together with other drugs included in the national guideline. 41 patients (31 severe and 10 moderate) received nimotuzumab. The median age was 62 years and the main comorbidities were hypertension, diabetes and cardiovascular disease. The antibody was very safe and the 14-day recovery rate was 82.9%. Inflammatory markers decreased over time. Patients did not show signs of fibrosis. Nimotuzumab is a safe antibody that might reduce inflammation and prevent fibrosis in severe and moderate COVID-19 patients. RPCEC00000369 (rpcec.sld.cu).
肺损伤和信号转导与转录激活因子1（STAT1）缺陷会导致新型冠状病毒2（SARS-CoV-2）感染时表皮生长因子受体（EGFR）过度表达。开展了一项I/II期试验，以评估抗EGFR抗体尼妥珠单抗对新型冠状病毒肺炎（COVID-19）患者的安全性和初步疗效。患者接受了1至3次输注，同时使用了国家指南中包含的其他药物。41例患者（31例重症和10例中度）接受了尼妥珠单抗治疗。中位年龄为62岁，主要合并症为高血压、糖尿病和心血管疾病。该抗体非常安全，14天恢复率为82.9%。炎症标志物随时间下降。患者未出现纤维化迹象。尼妥珠单抗是一种安全的抗体，可能会减轻重症和中度COVID-19患者的炎症并预防纤维化。RPCEC00000369（rpcec.sld.cu）
Zotero 插件